Pipeline

显示出强大临床性能和对患者有益的先进药物.

Pipeline
90
+
compounds, 单独或在合作或许可协议下开发的设备或适应症
investment
$7.1
b
R&D 2022年投资
Commitment
50
+
项目正处于中期和后期开发阶段
Novel
80
%
在临床开发具有新的作用机制的化合物

Pipeline

2023年5月25日更新

Sort By 
Focus Area
分子/资产阶段
分子/资产类型
设备资产阶段
设备资产类型
AGN-241622
Small Molecule Pharmaceutical Eye Care 2肾上腺素能受体
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Presbyopia
N ∕ A
N ∕ A phase1
phase1
AL002
TREM 2 Biologic Pharmaceutical Neuroscience Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
阿尔茨海默病
N ∕ A
N ∕ A phase2
phase2
TTX-030
Biologic Pharmaceutical Oncology CD39 Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-383
CD3-BCMA Biologic Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
多发性骨髓瘤
N ∕ A
N ∕ A phase1
phase1
QULIPTA™
Small Molecule Pharmaceutical CGRP Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
慢性偏头痛预防
US EU
US approved
EU submitted
approved
submitted
发作性偏头痛预防
US EU
US approved
EU submitted
approved
submitted
BOTOX®
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
阔肌突出
N ∕ A
N ∕ A phase3
phase3
咬肌突出
N ∕ A
N ∕ A phase3
phase3
Armour Thyroid
Large Molecule Pharmaceutical T3T4 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Hypothyroidism
N ∕ A
N ∕ A phase2
phase2
HPN-217
CD3-BCMA Biologic Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
复发的多发性骨髓瘤
N ∕ A
N ∕ A phase1
phase1
OnabotA X
Large Molecule Pharmaceutical SNARE Proteins Aesthetics Combination
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Glabellar Lines
N ∕ A
N ∕ A phase2
phase2
Forehead Lines
N ∕ A
N ∕ A phase2
phase2
ABBV-CLS-579
PTPN2 Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-647
Biologic Pharmaceutical Oncology PTK7
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-744
BET BDII Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Myelofibrosis
N ∕ A
N ∕ A phase1
phase1
ABBV-951
多巴胺受体 Small Molecule Pharmaceutical Neuroscience Combination
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
帕金森病
US EU
US submitted
EU submitted
submitted
submitted
Imbruvica
BTK Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
滤泡淋巴瘤
US , EU
US , EU phase3
phase3
套细胞淋巴瘤
N ∕ A
N ∕ A phase3
phase3
BOTOX®
Large Molecule Pharmaceutical Neuroscience SNARE Proteins
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
发作性偏头痛预防
N ∕ A
N ∕ A phase3
phase3
特发性震颤
N ∕ A
N ∕ A phase2
phase2
Clbr001 + swi019
Biologic Pharmaceutical Oncology Partner Asset CD19
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
BOTOX®
Large Molecule Pharmaceutical SNARE Proteins 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
IC BPS
N ∕ A
N ∕ A phase2
phase2
SKYRIZI®
Biologic Immunology IL-23 Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Crohn's Disease
US , EU
US , EU approved
approved
Psoriasis
US , EU
US , EU approved
approved
银屑病关节炎
US , EU
US , EU approved
approved
溃疡性结肠炎
N ∕ A
N ∕ A phase3
phase3
BoNTE
Large Molecule Pharmaceutical SNARE Proteins Aesthetics
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Glabellar Lines
N ∕ A
N ∕ A phase3
phase3
AGN-151607
SNAP25 Biologic Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
术后心房颤动
Global
Global phase2
phase2
ABBV-CLS-484
PTPN2 Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
JAB-3312
SHP2 Small Molecule Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
美国、欧盟、亚洲(不包括. China)
美国、欧盟、亚洲(不包括. China) phase1
phase1
阿唑南/阿维巴坦
Small Molecule Pharmaceutical PBP3 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
复杂的革兰氏阴性感染
N ∕ A
N ∕ A phase3
phase3
ABBV-514
Biologic Pharmaceutical Oncology N A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ALPN-101
Biologic 双重CD28-ICOS拮抗剂 Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
系统性红斑狼疮(SLE)
Global
Global phase2
phase2
ABBV-637
Biologic EGFR Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-927
anti-CD40 Biologic Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Elezanumab (abt - 555)
Biologic RGMa Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
脊髓损伤
N ∕ A
N ∕ A phase2
phase2
急性缺血性中风
N ∕ A
N ∕ A phase2
phase2
Veliparib
PARP Small Molecule Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Breast Cancer
N ∕ A
N ∕ A phase3
phase3
Ovarian Cancer
N ∕ A
N ∕ A phase3
phase3
ABBV-552
Small Molecule Pharmaceutical Neuroscience SV2A
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
阿尔茨海默病
N ∕ A
N ∕ A phase2
phase2
ABBV-903
Mpro Inhibitor Small Molecule Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
COVID
N ∕ A
N ∕ A phase1
phase1
ABBV-525
Small Molecule Pharmaceutical MALT1 Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
ABBV-319
Biologic ∕甾体ADC Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
血液肿瘤
N ∕ A
N ∕ A phase1
phase1
AGN-193408
Intracameral植入 Pharmaceutical Eye Care PGF2受体
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
开角型青光眼
N ∕ A
N ∕ A phase2
phase2
Occular高血压
N ∕ A
N ∕ A phase2
phase2
ABBV-453
Small Molecule Pharmaceutical Oncology Bcl-2
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
复发/难治性多发性骨髓瘤
N ∕ A
N ∕ A phase1
phase1
Eftoza
Biologic Pharmaceutical Oncology Trail Agonist
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
实体和血液肿瘤
N ∕ A
N ∕ A phase1
phase1
RINVOQ™
Immunology Small Molecule JAK1 Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
强直性脊柱炎
US , EU
US , EU approved
approved
特应性皮炎
US , EU
US , EU approved
approved
Axial SpA
US , EU
US , EU approved
approved
Crohn's Disease
US , EU
US , EU approved
approved
巨细胞动脉炎
US , EU
US , EU phase3
phase3
位患化脓性汗腺炎
N ∕ A
N ∕ A phase2
phase2
银屑病关节炎
US , EU
US , EU approved
approved
类风湿性关节炎
US , EU
US , EU approved
approved
系统性红斑狼疮(SLE)
N ∕ A
N ∕ A phase3
phase3
Takayasu指出动脉炎
JA
JA phase3
phase3
溃疡性结肠炎
US , EU
US , EU approved
approved
Vitiligo
N ∕ A
N ∕ A phase2
phase2
Venclexta™
Small Molecule Pharmaceutical Oncology Bcl-2
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
急性淋巴细胞白血病
N ∕ A
N ∕ A phase1
phase1
急性髓性白血病
US , EU
US , EU approved
approved
急性髓系白血病移植后
N ∕ A
N ∕ A phase3
phase3
慢性淋巴细胞白血病伴17p缺失
US , EU
US , EU approved
approved
一线慢性淋巴细胞白血病
US , EU
US , EU approved
approved
骨髓增生异常综合征
US , EU
US , EU phase3
phase3
多发性骨髓瘤
N ∕ A
N ∕ A phase3
phase3
复发性慢性淋巴细胞白血病
US , EU
US , EU approved
approved
ABBV-668
Immunology RIPK1 Small Molecule Pharmaceutical
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
溃疡性结肠炎
N ∕ A
N ∕ A phase2
phase2
Vraylar
5-HT2A拮抗剂 Small Molecule Pharmaceutical 多巴氨酸D2部分激动剂 Neuroscience 5-HT1A部分激动剂
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Adjunctive MDD
US
US approved
approved
ABBV-916
Biologic AßpE3 Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
阿尔茨海默病
N ∕ A
N ∕ A phase2
phase2
ABBV-1882
抗pd1和抗a4b7单抗 Biologic Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
HIV
N ∕ A
N ∕ A phase1
phase1
ABBV-4083
Wolbachia Small Molecule Pharmaceutical 其他专业
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
丝虫的疾病
N ∕ A
N ∕ A phase2
phase2
Epcoritamab
Biologic DuoBody-CD3xCD20 Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
复发性∕难治性弥漫性大b细胞淋巴瘤
US
US approved
approved
一线大b细胞淋巴瘤
US , EU
US , EU phase3
phase3
复发性滤泡性淋巴瘤
N ∕ A
N ∕ A phase3
phase3
b细胞非霍奇金淋巴瘤
N ∕ A
N ∕ A phase2
phase2
复发性慢性淋巴细胞白血病
N ∕ A
N ∕ A phase1
phase1
里希特氏综合征
N ∕ A
N ∕ A phase1
phase1
ABBV-RGX-314
Biologic Pharmaceutical Eye Care Partner Asset VEGF
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
湿性黄斑变性(视网膜下)
N ∕ A
N ∕ A phase3
phase3
湿性黄斑变性(脉络膜上)
N ∕ A
N ∕ A phase2
phase2
糖尿病视网膜病变(脉络膜上病变)
N ∕ A
N ∕ A phase2
phase2
CUG-252
IL-2 Mutein Biologic Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
系统性红斑狼疮(SLE)
N ∕ A
N ∕ A phase1
phase1
CLF065
GLP-2 agonist Biologic Immunology Pharmaceutical Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
IBD
N ∕ A
N ∕ A phase1
phase1
ABBV-CLS-7262
eIF2B Small Molecule Pharmaceutical Neuroscience
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
肌萎缩侧索硬化(ALS)
N ∕ A
N ∕ A phase2
phase2
消失性白质病(VWM)
N ∕ A
N ∕ A phase1
phase1
ABBV-932
Small Molecule Pharmaceutical DRD2 / DRD3激动剂 Neuroscience Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
广泛性焦虑症
N ∕ A
N ∕ A phase1
phase1
Lutikizumab
Biologic Immunology Pharmaceutical IL-1a ∕ 1b
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
位患化脓性汗腺炎
N ∕ A
N ∕ A phase2
phase2
Telisotuzumab vedotin (ABBV-399)
Biologic c-Met Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
非小细胞肺癌
N ∕ A
N ∕ A phase3
phase3
ABBV-151
Biologic GARP-TGF-β1 Pharmaceutical Oncology Partner Asset
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-400
Biologic cMET + Topo-1 ADC Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-706
SEZ6 + Topo-1 ADC Biologic Pharmaceutical Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
小细胞肺癌
N ∕ A
N ∕ A phase1
phase1
ABBV-181
Biologic Pharmaceutical anti-PD1 Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
ABBV-011
Biologic Pharmaceutical SEZ6 ADC Oncology
潜在的迹象
Region
Phase 1 Phase 2 Phase 3 Status
i 提交或批准时显示状态.
Status
i 提交或批准时显示状态.
小细胞肺癌
N ∕ A
N ∕ A phase1
phase1
Resonic
Body Contouring Device Cellulite Aesthetics
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
Cellulite
N A
N A development
development
Juvederm®volite®xc
面部美学 Device 皮肤畸形 Aesthetics Combination
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
细线还原
US , EU , JA
US , EU , JA confirmation
confirmation
Juvederm®volux®xc
面部美学 Device 下颌的轮廓定义 Aesthetics Combination
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
下颌的轮廓定义
US
US confirmation
confirmation
HArmonyCa™
面部美学 Device 面部轮廓 Aesthetics Combination
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
Facial Volume
N A
N A confirmation
confirmation
Tropoelastin
面部美学 Device 皮肤畸形 Aesthetics
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
Atrophic Scars
N A
N A confirmation
confirmation
Juvederm®volbella®xc
面部美学 Device Aesthetics Combination 眼眶下的挖空
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
眼眶下的挖空
US
US confirmation
confirmation
Juvederm®voluma®xc
面部美学 Device 皮肤畸形 Aesthetics Combination
潜在的迹象
Region
Concept Feasibility Development Confirmation
status
寺庙增大
N A
N A confirmation
confirmation
未发现结果 更改过滤或搜索条件.
Popular pages
External links

除非另有规定, 本网站出现的所有产品名称均为外围电竞所有或授权的商标.、其子公司或附属公司. 不得使用任何艾伯维商标, trade name, 在未经外围电竞事先书面授权的情况下，可以在本网站内使用或使用商业外观.除外，以识别外围电竞平台app的产品或服务.

版权所有©2023外围电竞. 北芝加哥，伊利诺伊州，美国.S.A.